Figure S1 OWSA Tornado diagram of net monetary benefit of rivaroxaban versus LMWH/VKA for the treatment of DVT – QALY based: 1 vs 2 (lifetime).
Patients requiring 3 months (a), 6 months (b), 12 months (c), and lifelong anticoagulation (d).
DVT, deep vein thrombosis; GP, general practitioner; HR, hazard ratio; LMWH, low molecular weight heparin; OP, outpatient; OWSA, one-way sensitivity analysis; PE, pulmonary embolism; QALY, quality-adjusted life-year; VKA, vitamin K antagonist; VTE, venous thromboembolism.